Bringing the very best science and medicine to our best equine friends
May 2015

Kindred Biosciences Announces First Quarter 2015 Financial Results

San Francisco, CA (May 8, 2015) Kindred Biosciences, Inc. (NASDAQ: KIN) today announced financial results for the first quarter ended March 31, 2015 and provided updates on its programs. Development Updates KindredBio continues to advance a diversified portfolio of validated molecules in a capital efficient manner and has over 20 programs in development. Some of the highlights include: The pivotal field trial of SentiKind, a KCNQ potassium channel agonist for post-operative pain in dogs, continues to enroll well and the Company expects to report topline results on this program in the second half of this year. The Company has completed …

Continue Reading